Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Eur J Nucl Med Mol Imaging ; 50(8): 2486-2500, 2023 07.
Artículo en Inglés | MEDLINE | ID: mdl-36877234

RESUMEN

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is one of the most promising therapeutic strategies in neuroendocrine neoplasms (NENs). Nevertheless, its role in certain tumor sites remains unclear. This study sought to elucidate the efficacy and safety of [177Lu]Lu-DOTATATE in NENs with different locations and evaluate the effect of the tumor origin, bearing in mind other prognostic variables. Advanced NENs overexpressing somatostatin receptors (SSTRs) on functional imaging, of any grade or location, treated at 24 centers were enrolled. The protocol consisted of four cycles of 177Lu-DOTATATE 7.4 GBq iv every 8 weeks (NCT04949282). RESULTS: The sample comprised 522 subjects with pancreatic (35%), midgut (28%), bronchopulmonary (11%), pheochromocytoma/ paraganglioma (PPGL) (6%), other gastroenteropancreatic (GEP) (11%), and other non-gastroenteropancreatic (NGEP) (9%) NENs. The best RECIST 1.1 responses were complete response, 0.7%; partial response, 33.2%; stable disease, 52.1%; and tumor progression, 14%, with activity conditioned by the tumor subtype, but with benefit in all strata. Median progression-free survival (PFS) was 31.3 months (95% CI, 25.7-not reached [NR]) in midgut, 30.6 months (14.4-NR) in PPGL, 24.3 months (18.0-NR) in other GEP, 20.5 months (11.8-NR) in other NGEP, 19.8 months (16.8-28.1) in pancreatic, and 17.6 months (14.4-33.1) in bronchopulmonary NENs. [177Lu]Lu-DOTATATE exhibited scant severe toxicity. CONCLUSION: This study confirms the efficacy and safety of [177Lu]Lu-DOTATATE in a wide range of SSTR-expressing NENs, regardless of location, with clinical benefit and superimposable survival outcomes between pNENs and other GEP and NGEP tumor subtypes different from midgut NENs.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales , Tumores Neuroendocrinos , Compuestos Organometálicos , Paraganglioma , Feocromocitoma , Humanos , Octreótido/efectos adversos , Tumores Neuroendocrinos/patología , Pronóstico , Receptores de Somatostatina , Compuestos Organometálicos/efectos adversos
2.
Sci Rep ; 14(1): 19907, 2024 08 28.
Artículo en Inglés | MEDLINE | ID: mdl-39198537

RESUMEN

The ability of 18F-FDG positron emission tomography (PET) to track disease activity and treatment response in patients with Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) remains unclear. Here, we assessed whether 18F-FDG uptake is a marker of disease activity and treatment response in AS or PsA, and explored the ability of 18F-FDG to predict treatment response. Patients with AS (n = 16) or PsA (n = 8) who were scheduled to initiate treatment with biologics were recruited. Participants underwent a clinical evaluation and an 18F-FDG scan prior to therapy initiation. Eleven participants underwent a follow-up 18F-FDG scan 3 months post-treatment. Images were quantified using a composite measure that describes the inflammatory status of the patient. Clinically involved joints/entheses had higher 18F-FDG uptake compared to unaffected areas (median difference > 0.6, p < 0.01). Among patients with AS, pre-treatment 18F-FDG uptake was strongly associated with disease activity (r = 0.65, p = 0.006). Longitudinal 18F-FDG scans demonstrated that decreases in uptake at 3 months were associated to clinical response (ßΔgSUVmax > 8.5, p < 0.001). We found no significant association between pre-treatment 18F-FDG uptake and subsequent clinical response. 18F-FDG PET shows potential as a marker of disease activity in AS and PsA, allowing for monitorization of biological treatment efficacy in these patients.


Asunto(s)
Artritis Psoriásica , Fluorodesoxiglucosa F18 , Tomografía de Emisión de Positrones , Espondilitis Anquilosante , Humanos , Artritis Psoriásica/diagnóstico por imagen , Artritis Psoriásica/tratamiento farmacológico , Espondilitis Anquilosante/diagnóstico por imagen , Espondilitis Anquilosante/tratamiento farmacológico , Masculino , Femenino , Adulto , Tomografía de Emisión de Positrones/métodos , Persona de Mediana Edad , Resultado del Tratamiento , Biomarcadores , Radiofármacos
3.
Clin Nucl Med ; 45(2): e122-e124, 2020 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-31714280

RESUMEN

Immunoglobulin G4-related disease (IgG4-RD) is a systemic inflammatory condition that can manifest in atypical locations. We present the case of a middle-aged woman presenting with isolated IgG4-RD of left maxilla and nasal septum, confirmed with F-FDG PET/CT. She achieved complete metabolic response with multiple pharmacologic treatment, but 1 year later, she experienced local relapse, and FDG PET/CT found new additional lesions in humeral vasculature and lungs. This case illustrates the usefulness of FDG PET/CT for initial evaluation and monitoring of IgG4-RD with unusual nasomaxillary involvement.


Asunto(s)
Fluorodesoxiglucosa F18 , Enfermedad Relacionada con Inmunoglobulina G4/diagnóstico por imagen , Maxilar/diagnóstico por imagen , Tabique Nasal/diagnóstico por imagen , Tomografía Computarizada por Tomografía de Emisión de Positrones , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Recurrencia
4.
Reumatol Clin (Engl Ed) ; 15(5): e30-e32, 2019.
Artículo en Inglés, Español | MEDLINE | ID: mdl-28583785

RESUMEN

Cogan's syndrome is a rare autoimmune disease that usually affects young Caucasian adults and is classically defined as the combination of nonsyphilitic interstitial keratitis and audiovestibular symptoms resembling Meniere's disease, both of them developed in an interval of less than two years. Nevertheless, cases with atypical ophthalmologic and audiovestibular features, with systemic manifestations or affecting children and older patients have also been reported, expanding the clinical spectrum of Cogan's syndrome. Herein, we present the case of a late-onset Cogan's syndrome associated with a large-vessel vasculitis.


Asunto(s)
Aortitis/complicaciones , Síndrome de Cogan/complicaciones , Edad de Inicio , Anciano de 80 o más Años , Aortitis/diagnóstico por imagen , Síndrome de Cogan/diagnóstico , Femenino , Humanos , Tomografía Computarizada por Tomografía de Emisión de Positrones , Arteria Subclavia/diagnóstico por imagen
8.
Reumatol. clín. (Barc.) ; 15(5): e30-e32, sept.-oct. 2019. ilus
Artículo en Inglés | IBECS (España) | ID: ibc-189417

RESUMEN

Cogan's syndrome is a rare autoimmune disease that usually affects young Caucasian adults and is classically defined as the combination of nonsyphilitic interstitial keratitis and audiovestibular symptoms resembling Meniere's disease, both of them developed in an interval of less than two years. Nevertheless, cases with atypical ophthalmologic and audiovestibular features, with systemic manifestations or affecting children and older patients have also been reported, expanding the clinical spectrum of Cogan's syndrome. Herein, we present the case of a late-onset Cogan's syndrome associated with a large-vessel vasculitis


El síndrome de Cogan es una enfermedad autoinmune rara, que afecta frecuentemente a pacientes jóvenes de raza caucásica y que se define clásicamente por la combinación de queratitis intersticial no sifilítica y síntomas audiovestibulares similares a una enfermedad de Ménière, que se desarrollan en un intervalo de menos de 2 años. Sin embargo, se han descrito casos con manifestaciones oftalmológicas o audiovestibulares atípicas, con síntomas sistémicos o que afectan a niños o pacientes ancianos, expandiendo de este modo el espectro clínico del síndrome de Cogan. Presentamos aquí el caso de un síndrome de Cogan de inicio tardío asociado con una vasculitis de gran vaso


Asunto(s)
Humanos , Femenino , Anciano de 80 o más Años , Aortitis/complicaciones , Síndrome de Cogan/complicaciones , Edad de Inicio , Aortitis/diagnóstico por imagen , Síndrome de Cogan/diagnóstico , Tomografía de Emisión de Positrones , Tomografía Computarizada por Rayos X , Arteria Subclavia/diagnóstico por imagen
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA